drugset
drugset / Trial / NCT02053454

A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

NCT02053454 ↗

Phase 1 Completed 12 enrolled Alnylam Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of patisiran (ALN-TTR02) in Japanese subjects

Timeline

Start
2014-01
Primary completion
2014-03
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Patisiran Small interfering RNA (siRNA) — Intravenous

Indications

No indication recorded.